Webb27 mars 2024 · The board of directors of Hansoh Pharmaceutical Group Company Limited announced that " HS-10390 tablets ", a Category 1 innovative drug self-developed by Changzhou Hansoh Pharmaceutical Company Limited and Shanghai Hansoh BioMedical Technology Company Limited both being subsidiaries of the Company, has been granted … http://www.hansoh.cn/en/news/512750.htm
上海翰森生物医药科技有限公司 - 企查查
Webb11 okt. 2024 · Hansoh will have the exclusive commercial rights to these therapeutics in China and OliX Pharmaceuticals will have the rights in the rest of the world. OliX Pharmaceuticals will receive initial upfront payment of USD 6.5 million with up to USD 450 million plus royalties based on key milestones. WebbHDP-101; Anti-CD269-ADC; Anti-CD269-amanitin-ADC Heidelberg Pharma in collaboration with Heading Medicine Co. Ltd/ Hertuzumab Vedotin Rongchang Pharmaceuticals / MabPlex (Yantai, China). HKT288 (CDH6-ADC) Novartis and ImmunoGen; HS-20089 Hansoh BioMedical R&D Company ( Shanghai Hansoh Biomedical Co., Ltd ; HTI-1066 … ct head beam hardening
Hansoh Health Technology Co., Ltd and Jiangsu Hansoh …
Webbför 2 dagar sedan · Cormorant Asset Management and Hansoh Pharmaceutical Group Company Limited Launches Blossom Biosciences Hansoh Bio on LinkedIn 1 Like Comment Share Hansoh Bio 3,780 followers ... WebbHansoh Pharma Ranked Among 2024 Top 100 Chinese Pharmaceutical Innovative Companies and China's Top 5 Pharmaceutical Innovation and Upgrading Role Models Recently, HealthCare Executive, an authoritative media in the pharmaceutical industry, released the rankings of 2024 Top 100 Chinese Pharmaceutical In... Read more 2024 09 … Webb简介: 上海翰森生物医药科技有限公司(曾用名:上海捷森药物化学科技有限公司),成立于2011年,位于上海市,是一家以从事研究和试验发展为主的企业。. 企业注册资 … ct head beam hardening artifact